Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant administration of a GRM and CYP3A inhibitors. The GRM may be, e.g., mifepristone； the CYP3A inhibitors or steroidogenesis inhibitors (collectively "inhibitors") may be, e.g., ketoconazole or itraconazole. Inhibitors may cause toxicity or other serious adverse reactions； concomitant administration of inhibitors with other drugs may increase the risk of such toxicity and adverse reactions due to the inhibitors and/or the other drugs. Applicant has surprisingly found that GRMs may be administered to subjects receiving inhibitors without increasing the risk of adverse reactions； for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole or itraconazole, providing safe concomitant administration of the GRM and ketoconazole or itraconazole. In embodiments, the GRM dose may be reduced during concomitant administration of the GRM with inhibitors.El solicitante proporciona métodos para tratar enfermedades que incluyen el síndrome de Cushing y los cánceres sensibles a las hormonas mediante la administración concomitante de un modulador del receptor de glucocorticoides (GRM) y los inhibidores de esteroidogénesis, y mediante la administración concomitante de un inhibidor de GRM y CYP3A. El GRM puede ser, por ejemplo, mifepristona； los inhibidores de CYP3A o los inhibidores de esteroidogénesis (colectivamente ''inhibidores'') pueden ser, por ejemplo, ketoconazol o itraconazol. Los inhibidores pueden causar toxicidad u otras reacciones adversas graves； la administración concomitante de inhibidores con otros fármacos puede aumentar el riesgo de dicha toxicidad y reacciones adversas debido a los inhibidores y/u otros fármacos. El solicitante ha encontrado sorprendentemente que los GRM pueden administrarse a su
